Jeff Thompson, a non-executive director of aesthetics company Sinclair Pharma, purchased 200,000 ordinary shares in the group on Wednesday at an average price of 23.1p each. Thompson held 350,000 ordinary shares in Sinclair following the £46,200 purchase. Sinclair announced on Monday that revenue had grown 20% to £45.3m in its pre-close trading update for the financial year ended 31 December, predicting a "modest" EBITDA profit for the year as a whole. As of 1240 GMT, shares had bumped up ...Den vollständigen Artikel lesen ...